3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1
2
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
2
NETWORK
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
437
Breast Neoplasms
382
Neoplasms
290
Prostatic Neoplasms
192
Neoplasm Metastasis
154
Multiple Myeloma
147
Colorectal Neoplasms
123
Lung Neoplasms
104
Ovarian Neoplasms
102
Parkinson Disease 4, Autosomal Dominant Lewy Body
98
Melanoma
95
Lymphoma, Follicular
94
Recurrence
88
Lymphoma, Non-Hodgkin
82
Papillomavirus Infections
81
Leukemia, Lymphocytic, Chronic, B-Cell
81
Carcinoma, Hepatocellular
80
Stomach Neoplasms
76
Small Cell Lung Carcinoma
72
Leukemia, Myeloid, Acute
70
Pancreatic Neoplasms
66
Pain
66
Uterine Cervical Neoplasms
64
Carcinoma, Renal Cell
64
Keratosis, Actinic
63
Urinary Bladder Neoplasms
59
Lymphoma, Large B-Cell, Diffuse
53
Myasthenia Gravis
52
Leiomyoma
49
Carcinoma
49
Interventions
anlotinib
1
Tablets
1
Rosuvastatin Calcium
1
Midazolam
1
Digoxin
1
Dacarbazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
INDUSTRY
×
Sarcoma, Alveolar Soft Part
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled